Especially as Poly (ADP-ribose) polymerase inhibitors have shown clinical benefit for treatment of breast or ovarian cancer with the presence of a BRCA1 or BRCA2 pathogenic variant [1,2], identifying these variants is more important than ever. This evidence concerns the gene BRCA1 and ovarian cancer.